Company news
Cogent Biosciences, Inc. (NASDAQ:COGT) news
Cogent Biosciences, Inc. news releases on 6ix. Latest, Jun 2, 2022: Cogent Biosciences Announces Annual Meeting of Stockholders
Press releases — page 3
Cogent Biosciences Announces Annual Meeting of Stockholders
June 1, 2022
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
May 11, 2022
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 9, 2022
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
May 5, 2022
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
April 10, 2022
Cogent Biosciences to Host Virtual R&D Investor Event
March 28, 2022
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results
March 14, 2022
Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022
March 7, 2022
Cogent Biosciences Provides 2022 Corporate Guidance
January 4, 2022
Cogent Biosciences to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
November 21, 2021
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results
November 9, 2021
Cogent Biosciences to Present Virtually at Jefferies London Healthcare Conference 2021
November 1, 2021
Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetration
October 6, 2021
Cogent Biosciences to Present Preclinical Data on Bezuclastinib at AACR-NCI-EORTC Conference
September 30, 2021
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
August 15, 2021
Cogent Biosciences to Present at Wedbush PacGrow Virtual Healthcare Conference 2021
July 26, 2021
Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021
June 28, 2021
Cogent Biosciences to Present at Jefferies Virtual Healthcare Conference 2021
May 25, 2021
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
May 11, 2021
Cogent Biosciences Appoints Evan Kearns as Chief Legal Officer
May 2, 2021
Cogent Biosciences Announces Creation of Cogent Research Team
April 5, 2021
Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
March 15, 2021
Cogent Biosciences Appoints Accomplished Finance Executive Todd E. Shegog to its Board of Directors
February 21, 2021
Cogent Biosciences to Present at Virtual 10th Annual SVB Leerlink Global Healthcare Conference 2021
February 17, 2021
Cogent Biosciences to Present at LifeSci Partners Virtual Precision Oncology Day 2021
February 10, 2021
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
December 3, 2020
Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer
November 29, 2020
Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock
November 29, 2020
Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference
November 19, 2020
Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020
November 17, 2020
Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference
November 11, 2020
Cogent Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
November 8, 2020
Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
November 4, 2020
Cogent Biosciences Appoints Andrew Robbins as Chief Executive Officer
October 25, 2020
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
October 4, 2020
Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO
August 30, 2020
Unum Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
August 10, 2020
Unum Therapeutics Inc. Announces Acquisition of Kiq LLC
July 5, 2020
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
May 10, 2020
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates
March 25, 2020
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
March 19, 2020
Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers
March 1, 2020
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
January 28, 2020
Unum Therapeutics Announces New Data at the American Society of Hematology (ASH) Annual Meeting
December 6, 2019
Unum Therapeutics to Present at Upcoming Investor Conference
November 14, 2019
Unum Therapeutics Reports Third Quarter 2019 Financial Results
November 11, 2019
Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 4, 2019
Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers
November 3, 2019
Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting
October 1, 2019